OLD National Bancorp IN Sells 5,279 Shares of Pfizer Inc. (NYSE:PFE)

Share on StockTwits

OLD National Bancorp IN decreased its holdings in shares of Pfizer Inc. (NYSE:PFE) by 2.2% in the 3rd quarter, HoldingsChannel.com reports. The fund owned 237,539 shares of the biopharmaceutical company’s stock after selling 5,279 shares during the quarter. OLD National Bancorp IN’s holdings in Pfizer were worth $8,535,000 at the end of the most recent quarter.

Several other institutional investors have also modified their holdings of PFE. Nuveen Asset Management LLC raised its position in shares of Pfizer by 2,240.5% during the 2nd quarter. Nuveen Asset Management LLC now owns 36,086,254 shares of the biopharmaceutical company’s stock valued at $1,563,256,000 after acquiring an additional 34,544,423 shares during the last quarter. Natixis bought a new stake in shares of Pfizer during the 2nd quarter valued at $258,466,000. Invesco Ltd. raised its position in shares of Pfizer by 14.6% during the 2nd quarter. Invesco Ltd. now owns 21,118,606 shares of the biopharmaceutical company’s stock valued at $914,857,000 after acquiring an additional 2,693,349 shares during the last quarter. DNB Asset Management AS raised its position in shares of Pfizer by 241.0% during the 3rd quarter. DNB Asset Management AS now owns 3,734,044 shares of the biopharmaceutical company’s stock valued at $134,164,000 after acquiring an additional 2,638,873 shares during the last quarter. Finally, Thoroughbred Financial Services LLC raised its position in shares of Pfizer by 4,297.8% during the 2nd quarter. Thoroughbred Financial Services LLC now owns 2,656,678 shares of the biopharmaceutical company’s stock valued at $265,668,000 after acquiring an additional 2,596,269 shares during the last quarter. Institutional investors own 71.66% of the company’s stock.

Several equities analysts have recently issued reports on the stock. Credit Suisse Group reissued a “neutral” rating on shares of Pfizer in a report on Monday, August 12th. DZ Bank raised shares of Pfizer from a “sell” rating to a “hold” rating and set a $36.00 price target for the company in a report on Wednesday, August 28th. ValuEngine raised shares of Pfizer from a “sell” rating to a “hold” rating in a report on Wednesday, October 2nd. Bank of America assumed coverage on shares of Pfizer in a report on Wednesday, October 16th. They issued a “neutral” rating and a $37.00 price target for the company. Finally, Zacks Investment Research raised shares of Pfizer from a “sell” rating to a “strong-buy” rating and set a $38.00 price target for the company in a report on Tuesday, October 1st. Twelve analysts have rated the stock with a hold rating, four have assigned a buy rating and one has given a strong buy rating to the company. The company currently has an average rating of “Hold” and a consensus target price of $44.47.

NYSE PFE traded up $0.05 on Tuesday, reaching $36.51. The company had a trading volume of 10,175,682 shares, compared to its average volume of 16,028,038. The firm has a market capitalization of $202.08 billion, a price-to-earnings ratio of 12.17, a price-to-earnings-growth ratio of 2.16 and a beta of 0.66. The company has a debt-to-equity ratio of 0.60, a quick ratio of 1.21 and a current ratio of 1.47. Pfizer Inc. has a 1-year low of $33.97 and a 1-year high of $46.47. The company’s fifty day moving average is $36.25 and its 200-day moving average is $39.64.

Pfizer (NYSE:PFE) last announced its earnings results on Monday, July 29th. The biopharmaceutical company reported $0.80 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.75 by $0.05. The firm had revenue of $13.26 billion during the quarter, compared to analyst estimates of $13.43 billion. Pfizer had a net margin of 23.58% and a return on equity of 28.10%. The company’s revenue for the quarter was down 1.5% compared to the same quarter last year. During the same period in the prior year, the business earned $0.77 EPS. On average, research analysts forecast that Pfizer Inc. will post 2.82 earnings per share for the current year.

The business also recently announced a quarterly dividend, which will be paid on Monday, December 2nd. Investors of record on Friday, November 8th will be paid a $0.36 dividend. This represents a $1.44 dividend on an annualized basis and a yield of 3.94%. The ex-dividend date is Thursday, November 7th. Pfizer’s payout ratio is presently 48.00%.

In related news, major shareholder Pfizer Inc bought 50,000 shares of Pfizer stock in a transaction that occurred on Tuesday, September 17th. The stock was purchased at an average cost of $18.00 per share, with a total value of $900,000.00. The acquisition was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director Scott Gottlieb bought 3,000 shares of Pfizer stock in a transaction that occurred on Friday, August 23rd. The stock was bought at an average cost of $34.72 per share, with a total value of $104,160.00. Following the completion of the purchase, the director now owns 3,000 shares in the company, valued at approximately $104,160. The disclosure for this purchase can be found here. 0.09% of the stock is currently owned by corporate insiders.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It offers medicines and vaccines in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases under the Lyrica, Chantix/Champix, Eliquis, Ibrance, Sutent, Xalkori, Inlyta, Xtandi, Enbrel, Xeljanz, Eucrisa, BeneFix, Genotropin, and Refacto AF/Xyntha brands.

Recommended Story: What is Net Asset Value (NAV)?

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE).

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Head-To-Head Comparison: ReneSola  versus BE Semiconductor Industrs
Head-To-Head Comparison: ReneSola versus BE Semiconductor Industrs
Analyzing Avaya  & Its Peers
Analyzing Avaya & Its Peers
JPMorgan Chase & Co. Reiterates “€75.00” Price Target for Symrise
JPMorgan Chase & Co. Reiterates “€75.00” Price Target for Symrise
JPMorgan Chase & Co. Analysts Give Hannover Re  a €133.00 Price Target
JPMorgan Chase & Co. Analysts Give Hannover Re a €133.00 Price Target
Morgan Stanley Reiterates “€9.50” Price Target for E.On
Morgan Stanley Reiterates “€9.50” Price Target for E.On
Moelis & Co  Receives Average Rating of “Hold” from Brokerages
Moelis & Co Receives Average Rating of “Hold” from Brokerages


 
© 2006-2019 Zolmax.